3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
4
Endocrine
4
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
CNS
1
Conditions
Sarcoma
9
Osteosarcoma
4
Sarcoma, Ewing
3
Rhabdomyosarcoma
3
Neuroblastoma
3
Neoplasms
3
Medulloblastoma
3
Glioma
3
Ependymoma
3
Central Nervous System Neoplasms
3
Carcinosarcoma
3
Wilms Tumor
2
Rhabdoid Tumor
2
Recurrence
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioblastoma
2
Endometrial Neoplasms
2
Carcinoma, Endometrioid
2
Breast Neoplasms
2
Xanthogranuloma, Juvenile
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Pathologic Complete Response
1
Interventions
Quality of Life
2
Fluorodeoxyglucose F18
2
tivozanib
1
tislelizumab
1
surufatinib
1
romidepsin
1
repotrectinib
1
olaparib
1
lutetium Lu 177 dotatate
1
fludarabine phosphate
1
fludarabine
1
entrectinib
1
atezolizumab
1
amino-acid, glucose, and electrolyte solution
1
alectinib
1
Surveys and Questionnaires
1
Poly(ADP-ribose) Polymerase Inhibitors
1
Patient Reported Outcome Measures
1
PM 01183
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Lactones
1
Irinotecan
1
Interleukin-2
1
Immunotherapy
1
FAPI-46
1
Drug Therapy
1
Depsipeptides
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
olaparib
×
Sarcoma
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled